Stivarga Approved for Liver Cancer

THURSDAY, April 27, 2017 — U.S. Food and Drug Administration approval of the anti-cancer drug Stivarga (regorafenib) has been expanded to include liver cancer, the agency said Thursday in a news release.
Stivarga, among a class of drugs called…
Source: Topamax